If you expected earth-shattering news about a new development from Johnson & Johnson at the JP Morgan Healthcare Conference on Monday, you were disappointed. J&J Chairman and CEO Alex Gorsky didn't make any big revelations.
Continue Reading Below
J&J CEO Alex Gorsky. Source: J&J
However, if you're a J&J shareholder, Gorsky's presentation probably left you feeling pretty good. He made a good case for why J&J should be viewed as one of the most successful companies in the world. Here are 15 numbers from Gorsky's talk that should bring smiles to investors' faces.
J&J is one of only three companies on the planet to have a AAA credit rating. While this is certainly something that bond holders are happy about, shareholders can also appreciate the stability that it represents. The number one also reflects J&J's position in terms of market capitalization among healthcare companies.
This is the number of years J&J is targeting to achieve operational savings of more than $1 billion.
Continue Reading Below
In the last year, J&J had six new pharmaceutical products reach $1 billion or more in sales. Joaquin Duato, Worldwide Chairman of Pharmaceuticals, added during the question and answer session following Gorsky's presentation that two other drugs should attain the billion-dollar sales level soon.
This is the approximate percent compound annual growth rate for J&J's sales from 1994 through 2013. That's a pretty solid record, especially considering that there was a major global economic crisis during the period.
J&J now has 10 medical device and diagnostics platforms with over $1 billion in annual sales. The number also reflects the total major pharmaceutical regulatory filings that J&J expects between 2013 and 2017.
There were at least 20 phase 3 clinical studies initiated in 2014 by J&J. The company also anticipates 20 major consumer product launches during 2015.
Gorsky stated that the company expects 25 major pharmaceutical line extensions between 2013 and 2017.
This was the most-cited number of all. J&J has been on Fortune magazine's Most Admired Companies List for 30 years. The healthcare giant also had at least 30 medical device and diagnostics approvals or pending filings as of the third quarter of 2014. J&J also expects to have 30 major medical device and diagnostics filings between 2014 and 2016. Then there's the really impressive statistic: for 30 consecutive years, J&J has increased adjusted earnings.
J&J has made 34 deals since 2010 to build its strong oncology portfolio, which includes drugs such as Doxil, Imbruvica, and Zytiga.
There have been at least 50 major new medical device and diagnostics product launches by J&J since 2012.
Dividend aristocrat? Oh, yes. J&J has increased dividends for 52 years in a row -- and counting.
This is the percentage of J&J's 2013 sales stemming from outside the U.S. Over one-fifth of all sales came from emerging markets.
There aren't too many weaklings in J&J's medical devices & diagnostics lineup. 85% of the segment's sales stem from platforms ranking either No. 1 or No. 2 in their categories.
J&J has been in operation since 1886. And the 128-year-old is still quite spry.
That's the number of dollars J&J has invested in innovation between 1994 and 2013. Around $100 billion of that total was on internal initiatives, while $80 billion or so went to fund external deals.
Paint by numbers
What Alex Gorsky basically did at the JP Morgan conference was to paint by numbers. He painted the picture of a great company using lots of figures and statistics. When you have numbers like J&J does, who could blame a CEO from throwing them around?
I'll offer up one more number: two. There are two things investors should take away from all of this. First, many of Gorsky's figures point to how solid J&J is. Second, many of the numbers also point to how innovative the company is. Anytime you can combine solid with innovative, there is probably a good investment to be made. That's something you can count on.
For more Foolish coverage of the JP Morgan Healthcare Conference, click here.
The article 15 Numbers That Will Make Johnson & Johnson Investors Giddy originally appeared on Fool.com.
Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.